Literature DB >> 7526536

Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes.

N D Christensen1, R Kirnbauer, J T Schiller, S J Ghim, R Schlegel, A B Jenson, J W Kreider.   

Abstract

Antibodies reactive to HPV types 6 and 11 were tested in ELISA and HPV-11 neutralization assays to determine whether these closely related types shared cross-reactive neutralizing epitopes. A series of HPV-11 neutralizing monoclonal antibodies (N-MAbs) that targeted conformational epitopes on infectious HPV-11 and HPV-11 L1 virus-like particles (VLPs) were tested for type-specificity of reactivity using intact HPV-6 L1 VLPs. Polyclonal antisera generated against intact HPV-6 L1 VLPs were also tested for HPV-11 neutralizing capacity using the athymic mouse xenograft system. The results demonstrated that conformationally dependent neutralizing epitopes on HPV-11 were very type-specific. Three of the four HPV-11 N-MAbs were negative for binding to HPV-6 L1 VLP, and the fourth demonstrated binding to HPV-6 L1 VLPs that was several orders of magnitude weaker than its binding to HPV-11 L1 VLP. The polyclonal anti-HPV-6 L1 VLP antiserum was only partially protective against HPV-11 infectivity even at a low dilution of 1:100. In contrast, polyclonal anti-HPV-11 L1 VLP antiserum was completely protective at dilutions greater than 1:10,000.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7526536     DOI: 10.1006/viro.1994.1649

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  36 in total

1.  Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope.

Authors:  R B Roden; A Armstrong; P Haderer; N D Christensen; N L Hubbert; D R Lowy; J T Schiller; R Kirnbauer
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  A cryo-electron microscopy study identifies the complete H16.V5 epitope and reveals global conformational changes initiated by binding of the neutralizing antibody fragment.

Authors:  Hyunwook Lee; Sarah A Brendle; Stephanie M Bywaters; Jian Guan; Robert E Ashley; Joshua D Yoder; Alexander M Makhov; James F Conway; Neil D Christensen; Susan Hafenstein
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

3.  Keratinocyte-secreted laminin 5 can function as a transient receptor for human papillomaviruses by binding virions and transferring them to adjacent cells.

Authors:  Timothy D Culp; Lynn R Budgeon; M Peter Marinkovich; Guerrino Meneguzzi; Neil D Christensen
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

4.  Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles.

Authors:  Timothy D Culp; Christin M Spatz; Cynthia A Reed; Neil D Christensen
Journal:  Virology       Date:  2007-01-12       Impact factor: 3.616

5.  Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implications.

Authors:  Maxime J J Fleury; Antoine Touzé; Marie-Christine Maurel; Thierry Moreau; Pierre Coursaget
Journal:  Protein Sci       Date:  2009-07       Impact factor: 6.725

Review 6.  The role of vaccines in the control of STDs: HPV vaccines.

Authors:  I H Frazer
Journal:  Genitourin Med       Date:  1996-12

Review 7.  Cervical cancer screening.

Authors:  Dorothy J Wiley; Bradley J Monk; Emmanuel Masongsong; Kristina Morgan
Journal:  Curr Oncol Rep       Date:  2004-11       Impact factor: 5.075

8.  Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1.

Authors:  Joseph J Carter; Greg C Wipf; Sarah F Benki; Neil D Christensen; Denise A Galloway
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

9.  Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein.

Authors:  Monica E Embers; Lynn R Budgeon; Martin Pickel; Neil D Christensen
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

10.  A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females.

Authors:  Andrea M Anonychuk; Chris T Bauch; Maraki Fikre Merid; Georges Van Kriekinge; Nadia Demarteau
Journal:  BMC Public Health       Date:  2009-10-31       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.